September 22, 2015

Perrigo received Food and Drug Administration approval for a therapeutic equivalent to Valeant’s BenzaClin acne treatment. 

September 17, 2015
The company’s president, CEO and chairman Joseph Papa has issued a letter to shareholders recommending against tendering their shares to Mylan.
September 14, 2015

The Perrigo offer notwithstanding, Mylan is committed and well-positioned to pursue the OTC segment independently given its global scale and capabilities, company says. 

September 11, 2015

Perrigo will begin shipments of the products to its retail and wholesale customers in the U.S in time for the 2016 cough and cold season. 

September 8, 2015

Under the terms of the offer, Perrigo shareholders would receive $75 in cash and 2.3 Mylan ordinary shares for each Perrigo ordinary share.

August 31, 2015

Perrigo expects the brand to bring in $3 million in the remainder of the year, with $10 million in projected full-year net sales. 

August 28, 2015

Mylan will now move forward with its plans to tender a formal offer directly to Perrigo’s shareholders. 

August 28, 2015

Perrigo announced Friday that it had completed its $224 million (€200 million) acquisition of several OTC brands from GlaxoSmithKline’s OTC portfolio.

August 14, 2015

Mylan announced will continue to urge its shareholders to vote in favor of its proposed acquisition of Perrigo despite Institutional Shareholder Services’ recommendation against the deal in a recent report.

July 29, 2015

Mylan on Wednesday announced that it received unconditional clearance from the European Commission under the European Union Merger Regulation for its acquisition of Perrigo Co., an Irish international manufacturer of private-label over-the-counter pharmaceuticals.

July 24, 2015

On Friday, Stichting Preferred Shares Mylan, an independent foundation established in the Netherlands, announced that it would exercise its full call option to purchase 488,388,431 preferred shares in Mylan.

June 19, 2015

The move gives Teva standing in Dutch court, should they decide to pursue action against Mylan.

June 16, 2015

Mylan’s largest shareholder has promised to back the company’s bid to buy Perrigo, which would help fend off Teva’s $40 billion takeover offer.

June 2, 2015

Actavis and Perrigo's application for a generic guaifenesin/PSE product approved by FDA. 

June 2, 2015

Perrigo's new OTC product portfolio acquired out of the GSK/Novartis joint venture are sold primarily throughout Europe and Brazil. 

May 29, 2015

Flonase tells an impressive sales story in its first 16 weeks on the shelf.

May 26, 2015

Acquisition target Perrigo recently filed a complaint to Irish Takeover Panel regarding Mylan proposal. 

May 20, 2015

Mergers and acquisitions among pharmaceutical companies has kicked into high gear this year, mirroring the larger trend sweeping across the entire spectrum of the health care industry since the implementation of the Affordable Care Act two years ago.

May 20, 2015

The gummy sub-segment within overall vitamins is not only still growing substantially, the dollar volume of that alternative delivery format has reached nowhere near its ceiling of potential, at least not yet. Overall, sales of vitamins for the 52 weeks ended Dec. 28, 2014, were up 0.4% to $6.5 billion across total U.S. multi-outlets, according to IRI.

May 20, 2015

Perrigo Animal Health in May announced its launch of PetArmor Joint Health Maximum, a supplement for dogs that contains glucosamine, chondroitin, MSM and manganese. It’s an opportunity for retailer’s to associate their store brand with a quality pet supplement.

May 12, 2015

Perrigo enhances softgel production with latest acquisition. 

May 6, 2015

Perrigo Animal Health introduces CosequinDS national brand equivalent in Walmart. 

April 24, 2015

Mylan has announced that it will commence with a formal offer to acquire generic drug maker Perrigo.

April 22, 2015

Perrigo on Tuesday rejected a proposed acquisition by Mylan.